Table 3.
Group | HR (beats/min) | PR (msec) | QRS (msec) | QT (msec) | P amplitude (µv) | R amplitude (µv) | ST height (µv) |
---|---|---|---|---|---|---|---|
CON (sal+sal) | 237.6±4.8 | 55.8±1.9 | 21.4±3.1 | 58.1±9.4 | 33.9±5.1 | 334.0±51.2 | 106.4±24.0 |
ISO (ISO+sal) | 282.6±27.8 | 48.9±4.0 | 21.5±2.7 | 57.1±10.6 | 56.1±18.8 | 294.6±21.5 | 66.1±32.5 |
ISO+PM | 239.8±8.9 | 51.2±2.5 | 25.1±4.2 | 47.4±5.4 | 30.0±8.2 | 409.8±103.7 | 17.4±5.54 |
CON+PM | 224.2±14.5 | 53.4±3.3 | 17.4±2.9 | 65.5±10.5 | 30.6±8.8 | 319.8±39.9 | 38.6±17.7 |
CON+ES (sal+ES) | 231.8±7.2 | 45.5±3.2 | 15.2±1.0 | 47.4±6.1 | 16.8±3.3 | 156.2±39.5 | 63.6±18.2 |
ISO+ES | 188.8±10.6* | 61.4±2.7* | 23.8±6.5 | 59.9±10.7 | 28.3±6.0* | 229.0±69.9 | 25.8±7.3* |
Statistically significant (p<0.05), CON: Control group, ISO: Isoproterenol, PM: Physical mixture (drug: polymer ratio of 1:10), ES: Electrosprayed sample with the drug: polymer ratios of 1:10 at total solution concentration of 20 % (w/v). The data were reported average ± SEM (standard error of mean).